Screening and evaluation of a novel nucleotide-degrading Levilactobacillus brevis grx821 with anti-hyperuricemia ability

Abstract

Hyperuricemia seriously impacts our health and life quality. Probiotics play a vital role in ameliorating hyperuricemia through decrease urate production by purine substance assimilation. However, most research screened probiotics based on the assimilation of purine nucleoside, ignoring nucleotides. Nucleosides are derived from nucleotides. We hypothesized that lactic acid bacteria with the ability of nucleotides assimilation might be better to reduce intestinal absorption of dietary purine substances. In this study, a total of 235 strains of lactic acid bacteria were isolated from Chinese traditional fermented foods and evaluated for their purine nucleotides assimilation ability. A new potential candidate Levilactobacillus (L.) brevis grx821 isolated from naturally fermented soy whey Suanjiangshui, with a strong ability to degrade purine nucleotides and purine nucleosides, effectively reduced the serum levels of UA and creatinine in hyperuricemia mice by 20.76% and 14.38%. Based on the evaluation of antibiotic susceptibility, production of nitrite and biogenic amines, and hemolytic activity, L. brevis grx821 can be considered safe. L. brevis grx821 showed good gastrointestinal tolerance in vitro and cow milk fermentation characteristics, and could be a promising candidate of dietary supplements for prevention of hyperuricemia. This study suggests a novel way screening potential probiotic candidate for hyperuricemia, which has great guiding significance in the dealing with hyperuricemia.